Arno Therapeutics, Inc.
ARNI
$0.0001
$0.000.00%
OTC PK
| 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | 09/30/2015 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.12M | 1.25M | 1.28M | 957.90K | 1.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.23M | 3.31M | 2.83M | 2.70M | 2.87M |
| Operating Income | -2.23M | -3.31M | -2.83M | -2.70M | -2.87M |
| Income Before Tax | -3.85M | -2.14M | -3.71M | -4.00M | -679.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.85M | -2.14M | -3.71M | -4.00M | -679.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.85M | -2.14M | -3.71M | -4.00M | -679.30K |
| EBIT | -2.23M | -3.31M | -2.83M | -2.70M | -2.87M |
| EBITDA | -2.23M | -3.31M | -2.82M | -2.69M | -2.87M |
| EPS Basic | -0.09 | -0.05 | -0.10 | -0.20 | -0.03 |
| Normalized Basic EPS | -0.05 | -0.03 | -0.06 | -0.12 | -0.02 |
| EPS Diluted | -0.09 | -0.05 | -0.10 | -0.20 | -0.03 |
| Normalized Diluted EPS | -0.05 | -0.03 | -0.06 | -0.12 | -0.02 |
| Average Basic Shares Outstanding | 44.71M | 41.56M | 38.77M | 20.41M | 20.41M |
| Average Diluted Shares Outstanding | 44.71M | 41.56M | 38.77M | 20.41M | 20.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |